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Supplementary Table 1: Patient Characteristics by Gender * 
A) Demographics and phenotype ** 
 Men (n = 4661) Women (n = 2454) *** 
Age at diagnosis: ****   
- Mean  37 yrs. (SD: 15) 40 yrs. (SD: 16) 
- <= 20 yrs. 660 (14·2%) 278 (11·4%) 
- 21 – 30 yrs. 1065 (22·8%) 442 (18.0%) 
- 31 – 40 yrs.  1084 (23·3%) 532 (21·7%) 
- 41 – 50 yrs. 904 (19·4%) 531 (21·7%) 
- 51 – 60 yrs. 550 (11·8%) 403 (16·4%) 
> 60 yrs. 397 (8·5%) 266 (10·8%) 
PSC sub-phenotype: ****   
 - classical PSC  4231 (90·8%) 2160 (88·0%) 
- small duct PSC  158 (3·4%) 96 (3.9%) 
- PSC / AIH variant 271 (5·8%) 198 (8·1%) 
Diagnosis year:   
- 1980 – 1984 144 (3·1%) 73 (3·0%) 
- 1985 – 1989 304 (6·5%) 120 (4·9%) 
- 1990 – 1994 524 (11·2%) 248 (10·1%) 
- 1995 – 1999 937 (20·1%) 477 (19·4%) 
- 2000 – 2004 1176 (25·2%) 623 (25·4%) 
- 2005 – 2010 1576 (33·8%) 913 (37·2%) 
IBD phenotype at baseline: ****   
- ulcerative colitis 1935 (45.4%) 823 (36.0) 
- Crohn’s disease 362 (8.5%) 233 (9·5) 
- indeterminate colitis 76 (1.8%) 37 (1·6) 
- no IBD 
  
1890 (44.3%) 
 
1190 (52.1) 
 
IBD phenotype at end of follow-up: ****   
- ulcerative colitis 2818 (61.0) 1168 (48.1) 
- Crohn’s disease 466 (10·1) 318 (13.1) 
- indeterminate colitis 143 (3·1) 67 (2·8) 
- no IBD  1193 (25·5) 874 (36.0.7) 
B) Clinical events **** Incidence rate per-100-pt. yrs. (95%. C.I.) 
Liver transplantation or death 5.58 (5.34-5.82) 5.16 (4.83-5.48) 
Hepatopancreatobiliary malignancy   
- overall 1.55 (1.41-1.68) 1.10 (0.94-1.25) 
-cholangiocarcinoma 1.28 (0.86-1.71) 0.90 (0.43-1.37) 
*  Data presented as absolute number (%) unless otherwise indicated. 
** Data presented only for patients in whom complete respective data are available. 
*** Six patients did not have gender data documented 
**** Indicates statistically significant differences of covariate frequency between all subgroups listed 
(p < 0·05). 
 
 
 
 
Supplementary Table 2: Patient Characteristics by PSC Sub-phenotype * 
A) Demographics and phenotype ** 
 Classical PSC  
(n= 6397) 
Small-duct PSC 
(n = 254) 
PSC / AIH variant 
(n = 470) 
No. of men  4232 (66·2%) 158 (62.2%) 271 (57.8%) 
Age at diagnosis:     
- Mean  39 yrs. (SD: 15·4) 37yrs. (SD: 14·8) 32 yrs. (SD: 15) 
- < 20 yrs. 779 (12·2%) 35 (13.8%) 126 (26.8%) 
- 21 – 30 yrs. 1323 (20·7%) 59 (23.2%) 126 (26.8%) 
- 31 – 40 yrs.  1456 (22·8%) 68 (26.8%) 93 (19·8%) 
- 41 – 50 yrs. 1327 (20·8%) 43 (16.9%) 65 (13·8%) 
- 51 – 60 yrs. 884 (13·8%) 32 (12.6%) 37 (7·9%) 
> 60 yrs. 625 (9·8%) 17 (6.7%) 23 (4·9%) 
Diagnosis year:     
- 1980 – 1984 213 (3.3%) 2 (0·8%) 2 (0·4%) 
- 1985 – 1989 404 (6·3%) 9 (3·5%) 11 (2·3%)  
- 1990 – 1994 723 (11·3%) 18 (7.1%) 32 (6·8%) 
- 1995 – 1999 1287 (20·1%) 47 (18·5%) 80 (17.0%) 
- 2000 – 2004 1603 (25·1%) 79 (31.1%) 120 (25·5%) 
- 2005 – 2010 2167 (33·9%) 99 (39.0%) 225 (47.9%) 
IBD phenotype at baseline:     
- ulcerative colitis 2535 (43.2%) 67 (27.9%) 159 (36.2%) 
- Crohn’s disease 545 (9.3%) 24 (10.0%) 26 (5·9%) 
- indeterminate colitis 98 (1·7%) 6 (2·5%) 9 (2.1%) 
- no IBD  2694 (45.9%) 143 (59.6%) 245 (55.8%) 
IBD phenotype at end of study:     
- ulcerative colitis 3682 (58.1%) 85 (33.5%) 222 (47·7%) 
- Crohn’s disease 718 (11·3%) 30 (11·8%) 38 (8·2%) 
- indeterminate colitis 185 (2·9%) 7 (2·8%) 18 (3·9%) 
- no IBD  1750 (27·6%) 132 (52.0%) 187 (40.2%) 
B) Clinical events ** Incidence rate per-100-pt. yrs. (95%. C.I.) 
Liver transplantation or death 5·62 (5.42 -5.83) 2·32 (1.67 – 3.00) 4·70 (3.97 – 5.43) 
Hepatopancreatobiliary malignancy    
-overall 1·52 (1.41 –1.63) 0·20 (0.00 –0.39) 0·43 (0·20 – 0·65) 
- cholangiocarcinoma 1·25 (0.90–1.60) No cases  0·37 (0·16 – 0·58) 
*  Data presented as absolute number (%) unless otherwise indicated. 
** Data presented only for patients in whom complete respective data are available. 
 
Supplementary Table 3: Patient Characteristics by IBD phenotype (at baseline) * 
A) Demographics and phenotype ** 
 Ulcerative colitis 
(n = 2761) 
Crohn’s Disease 
(n= 595) 
Indeterminate 
(n = 113) 
No IBD 
(n = 3082) 
No. of men 1935 (70·2) 362 (60.8) 76 (67·3) 1890 (61·4) 
Age at diagnosis:     
- Mean  37 yrs. (SD: 15)  38 yrs. (SD: 16)  35 yrs. (SD: 14)  40 yrs. (SD: 16)  
- <= 20 yrs. 410 (14·8%) 91 (15·3%) 17 (15·0%) 350 (11·4%) 
- 21 – 30 yrs. 646 (23·4%) 125 (21·0%) 36 (31·9%) 585 (19·0%) 
- 31 – 40 yrs.  671 (24·3%) 136 (22·9%) 24 (21·2%) 660 (21·4%) 
- 41 – 50 yrs. 510 (18·5%) 116 (19·5%) 17 (15·0%) 664 (21·6%) 
- 51 – 60 yrs. 336 (12·2%) 74 (12·4%) 13 (11·5%) 452 (14·7%) 
> 60 yrs. 188 (6·8%) 53 (8·9%) 6 (5·3%) 368 (12·0%) 
PSC sub-phenotype:     
 - classical PSC  2535 (91·8%) 545 (91·6%) 98 (86·7%) 2694 (87·4%) 
- small duct PSC  67 (2·4%) 24 (4·0%) 6 (5·3%) 143 (4.6%) 
- PSC / AIH variant 159 (5·8%) 26 (4·4%) 9 (8·0%) 245 (7·9%) 
Diagnosis year:     
- 1980 – 1984 75 (2·7%) 9 (1·5%) 4 (3·5%) 91 (3·0%) 
- 1985 – 1989 166 (6·0%) 23 (3·9%) 6 (5·3%) 167 (5·4%) 
- 1990 – 1994 327 (11·8%) 41 (6·9%) 16 (14·2%) 299 (9·7%) 
- 1995 – 1999 561 (20·3%) 104 (17·5%) 15 (13·3%) 620 (20·1%) 
- 2000 – 2004 705 (25·5%) 165 (27·7%) 27 (23·9%) 783 (25·4%) 
- 2005 – 2010 927 (33·6%) 253 (42·5%) 45 (39·8%) 1122 (36·4%) 
B) Clinical events ** Incidence rate per-100-pt. yrs. (95% C.I.) 
Liver transplantation or death 5.36 (5.06-5.67) 3.89 (3.30-4.47) 4.47 (3.07-5.88) 5.82 (5.51-6.13) 
Hepatopancreatobiliary malignancy     
-overall 1.48 (1.31-1.64) 1.21 (0.88-1.55) 1.43 (0.62-2.24) 1.34 (1.19-1.50) 
- cholangiocarcinoma 1.22 (0.72-1.72) 1.02 (0.03-2.02) 1.19 (0.00-3.07) 1.11 (0.60-1.62) 
*  Data presented as absolute number (%) unless otherwise indicated. 
** Data presented only for patients in whom complete respective data are available. 
 
 
Supplementary Table 4: Incidence Rates (IR) per-100-pt. yrs. of Liver transplantation / 
Death According to Phenotype 
 
Event: liver transplantation / death 
   
 Male Female 
 UC CD IC No-
IBD 
UC CD IC No-
IBD 
Classical 
PSC  
        
IR:  5.5 4.3 4.6 6.3 5.3 3.4 5.5 5.7 
1y survival:  94% 96% 97% 92% 95% 96% 100% 94% 
5y survival:  77% 80% 82% 71% 79% 85% 73% 77% 
10y survival: 59% 67% 73% 55% 61% 72% 62% 60% 
20y survival: 30% 52% 37% 31% 23% 67% 40% 35% 
sdPSC         
IR:  2.5 0.0 0.0 2.2 2.7 4.0 0.0 2.5 
1y survival:  96% 100% 100% 99% 100% 100% 100% 95% 
5y survival:  96% 100% 100% 89% 100% 88% 100% 86% 
10y survival: 96% 100% 100% 89% 75% 88% - 80% 
20y survival: 84% - - 82% 56% - - 67% 
PSC/AIH-
overlap 
        
IR:  4.1 4.8 2.1 3.9 5.2 6.6 0.0 5.5 
1y survival:  96% 100% 100% 96% 97% 92% 100% 96% 
5y survival:  86% 92% 83% 78% 79% 61% - 81% 
10y survival: 73% 69% 83% 68% 69% 41% - 56% 
20y survival: 45% 69% - 55% 30% 41% - 29% 
 
Supplementary Table 5: Incidence Rates (IR) per-100-pt. yrs. of HPB malignancy 
According to Phenotype 
 
Event: hepatopancreatobiliary (HPB) malignancy * 
 Male Female 
UC CD IC No-IBD UC CD IC No-
IBD 
Classical PSC         
IR; 1st yr. only: 3.1 2.2 3.5 3.8 2.2 2.1 1.9 2.6 
IR; overall: 1.6 1.6 1.4 1.7 1.5 0.6 1.5 1.1 
1y survival:  96% 97% 95% 94% 97% 97% 97% 96% 
5y survival:  92% 92% 93% 90% 92% 96% 91% 92% 
10y survival: 86% 87% 93% 86% 86% 95% 78% 90% 
20y survival: 70% 73% 82% 75% 68% 95% 78% 83% 
sdPSC         
IR; 1st yr. only: 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
IR; overall: 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.5 
1y survival:  100% 100% 100% 100% 100% 100% 100% 100% 
5y survival:  100% 100% 100% 100% 100% 100% 100% 98% 
10y survival: 100% 100% 100% 100% 89% 100% - 92% 
20y survival: 100% - - 100% 89% - - 92% 
PSC/AIH-
overlap 
        
IR; 1st yr. only: 1.5 6.5 0.0 0.7 0.0 0.0 0.0 0.8 
IR; overall: 0.7 2.0 0.0 0.2 0.2 1.2 0.0 0.1 
1y survival: 96% 92% 100% 99% 100% 100% 100% 99% 
5y survival:  94% 81% 100% 98% 98% 89% - 99% 
10y survival: 94% 81% 100% 98% 98% 89% - 99% 
20y survival: 94% 81% - 98% 98% - - 99% 
* For HPB malignancy, IR are provided for events in the 1st year only as well as overall 
 
 Supplementary Table 6: Univariate Risk Factors for Disease Progression * 
Risk factor Crude Hazard Ratio (95% C.I.) p value 
 
A) Liver transplantation / death 
Age at diagnosis ** 1·022 (1·019 – 1·025)  < 0·0001 
Gender   
Male 1 (reference)  
Female  0·88 (0·81– 0·96) 0·002 
PSC sub-phenotype    
- classical PSC 1 (reference)  
- small duct PSC 0·30 (0·21 – 0·42) < 0·001 
- PSC / AIH variant 0.81 (0·0.68 – 0.96) 0.015 
IBD phenotype (baseline)   
- ulcerative colitis  1 (reference)  
- Crohn’s disease 0.64 (0.53 – 0.76) <0.0001 
- indeterminate 0.86 (0.61 – 1.22) 0·40 
- no IBD 1.01 (0·93 – 1·10) 0·89 
IBD phenotype  
(prior-to-endpoint) *** 
  
- ulcerative colitis  1 (reference)  
- Crohn’s disease 0·62 (0·52 – 0·72) < 0·001 
- indeterminate 0·91 (0·68 – 1·21) 0·52 
- no IBD 0·90 (0·83 – 0·99) 0·03 
 
B) Hepatopancreatobiliary malignancy 
Age at diagnosis ** 1·03 (1·03 – 1·04) < 0·001 
Gender   
Male 1 (reference)  
Female  0·68 (0·57 – 0·80) < 0·001 
PSC biliary phenotype    
- classical PSC 1 (reference)  
- small duct PSC 0·15 (0·06 – 0·40) < 0·001 
- PSC / AIH variant 0·26 (0·15 – 0·44) < 0·001 
IBD phenotype  
(baseline) 
  
- ulcerative colitis  1 (reference)  
- Crohn’s disease 0·73 (0·54 – 0.96) 0·04 
- indeterminate 1·09 (0·61 – 1·94) 0·77 
- no IBD 0·88 (0·75 – 1·04) 0·14 
IBD phenotype  
(prior-to-endpoint) *** 
  
ulcerative colitis  1 (reference)  
- Crohn’s disease 0·68 (0·51 – 0·91) 0·008 
- indeterminate 0·94 (0·55 – 1·61) 0·82 
- no IBD 0·77 (0·65 – 0·92) 0·004 
*All analysis stratified by geographical region of participating centre and adjusted by patient year of diagnosis. 
** Per 1-yr. increase in age. 
*** Assessed as a time-dependent covariate 
 
Supplementary Table 7: Previously published clinical outcome studies in PSC * 
Geographical location Study type  Study period or last reported 
follow-up date 
– previously reported 
Maximum No. pts.  
 
– previously reported 
Multi-national 
Italy, Norway, Spain, Sweden, UK  Observational  1998 1,2 394 
Scandinavia Clinical trial 2009 3–5 219 ** 
Finland, the Netherlands, Norway, UK Investigative 
biomarker  
2012 6 305  
Germany and Sweden Observational 1989 – 2008 (Germany) 7,8 
1992 – 2005 (Sweden)  
345 
Germany and Norway Observational 2014 11 638 
Germany and Norway Investigative 
biomarker  
2006 – 2015 (Germany) 12 
2008 – 2012 (Norway) 
318 
Belgium    
Leuven Observational 1975 – 2012 13,14 240 
Canada 
Toronto, ON Observational 2009 15 168 
France 
Paris Observational 2008 16 150 
Germany 
Heidelberg  Observational / 
investigative 
biomarker  
2012 17–21 281 *** 
Hannover Observational 200610 273 
Hamburg and Hannover Observational 20139 509 
Italy    
Multi-regional Observational 1994 22 117  
The Netherlands    
Multi-regional Observational  2008 23–27 590 *** 
Sweden    
Multi-regional Observational 1992 28 305 
Stockholm Observational 1970 – 2004 29–31 604 
USA 
Multi-regional  Clinical trial 2009 32–34 150 
Multi-regional  Observational  1995 – 2005 33 784 
Minnesota Observational  1970 – 1997 36,37 174 
California Observational  2000 – 2006 38 169 
UK 
London Observational 2011 39 128 
London Observational 1990 – 2009 40 96 
London Observational 1972 – 1989 41 169 
* Comprises PSC cohorts ~ / >100 patients, which have contributed data to the international PSC Study Group (IPSCSG). Presented reports are likely to 
include those wherein more than one publication stems from a given cohort. 
** Includes post-hoc outcome analysis of patients included in prior clinical trials. 
*** Includes a subset of patients subject to an open-label study of endoscopic biliary intervention. 
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 Supplementary Figure 1:  Incidence of Cholangiocarcinoma by Age at PSC diagnosis 
 
 
Incidence rates of cholangiocarcinoma (CCA) according to the age at PSC diagnosis are presented for all cases in [A], 
excluding CCA cases diagnosed in the first year of PSC diagnosis [B] and restricted analysis to events within the first 
year of PSC diagnosis [C]. 
 
Supplementary Figure 2: Incidence of Clinical Events According to PSC Phenotype  
Kaplan-Meier estimates illustrating [A] transplant-free survival and [B] incidence rate of 
hepatopancreatobiliary malignancy, stratified according to PSC phenotype at diagnosis (unadjusted) Patients 
with unknown malignancy status at time of study completion were excluded from analysis in [B]. 
 
 
 
 
